Diagnostic Approach to Polycythemia Vera in Patients with Elevated Hemoglobin and Suppressed Erythropoietin

1. Initial Assessment and Likelihood of PV

• In adults presenting with markedly elevated hemoglobin/hematocrit together with serum erythropoietin below the normal adult range (≈10‑30 mU/mL), autonomous red‑cell production—characteristic of polycythemia vera—is the most probable diagnosis, and JAK2 mutation testing should be performed without delay. 1

• A low erythropoietin level effectively rules out secondary causes of erythrocytosis, in which erythropoietin would be inappropriately normal or elevated. 1

2. Immediate Molecular Testing

• JAK2 V617F mutation is detected in roughly 95 % of polycythemia vera cases; a positive result fulfills a major diagnostic criterion. 1

• If the JAK2 V617F test is negative, JAK2 exon 12 mutation analysis should be performed, as exon 12 alterations account for the majority of the remaining PV cases. 1

3. Supporting Laboratory Findings

• A complete blood count may reveal leukocytosis (>12 × 10⁹/L) and/or thrombocytosis (>400 × 10⁹/L), which strengthen the diagnostic impression but are not required for diagnosis. 1

• Bone‑marrow biopsy demonstrating panmyelosis with prominent erythroid and megakaryocytic proliferation serves as a minor diagnostic criterion when JAK2 mutation is present. 1

4. Formal Diagnostic Criteria (WHO‑style)

Diagnosis requires both major criteria plus at least one minor criterion. 1

Note: A hemoglobin threshold of 18.5 g/dL predicts true absolute erythrocytosis in only ~35 % of male PV patients; therefore, erythropoietin measurement and JAK2 testing are essential adjuncts. 1

5. Systematic Exclusion of Secondary Causes

• Arterial blood‑gas analysis and pulse‑oximetry to detect occult hypoxemia. 2
• Carboxyhemoglobin measurement when carbon‑monoxide exposure is possible. 2
• Renal and abdominal imaging (ultrasound or CT) to screen for renal cell carcinoma, hepatic neoplasms, or renal‑artery stenosis that could produce ectopic erythropoietin. 2
• Brain MRI if a cerebellar hemangioblastoma is clinically suspected. 2
• Transthoracic or trans‑esophageal echocardiography to identify right‑to‑left cardiac shunts. 2
• Overnight sleep study when obstructive sleep apnea is a concern. 2

6. Core Therapeutic Measures for All Patients

• Phlebotomy is required to keep hematocrit < 45 % (corresponding to hemoglobin < 16 g/dL in men and < 15 g/dL in women). 2

• Iron‑status monitoring should be performed regularly during chronic phlebotomy, as iron depletion can paradoxically increase the risk of cerebrovascular events. 2

• Avoidance of exogenous erythropoietin: administration of recombinant EPO in PV patients raises thromboembolic risk by 67 % (relative risk 1.67; 95 % CI 1.35‑2.06). [2][3]

7. Follow‑Up and Monitoring Protocol

• Hemoglobin/hematocrit should be checked every 4–8 weeks during the initial treatment phase, with interval extension once stable targets are achieved. [4][2]

• Complete blood count should be repeated periodically to detect emerging leukocytosis or thrombocytosis that may signal disease progression. 2

• At each visit, clinicians should assess for hyperviscosity symptoms (e.g., headache, visual changes, dizziness, aquagenic pruritus). 2

Diagnostic Evaluation of Normal EPO with Elevated Hemoglobin/Hematocrit

1. Significance of a Normal Erythropoietin Level

• A normal serum erythropoietin (EPO) level does not exclude polycythemia vera (PV); about 30 % of confirmed PV patients have EPO within the reference range, giving a sensitivity of roughly 70 % for a low‑EPO result in diagnosing PV. 5
• PV is essentially excluded when EPO is clearly elevated above the normal range, because an elevated EPO points toward secondary erythrocytosis rather than PV. 6

2. Immediate Diagnostic Actions When EPO Is Normal or Low

• In any adult with hemoglobin > 16.5 g/dL (men) or > 16.0 g/dL (women) or hematocrit > 49 % (men) / > 48 % (women), JAK2 mutation testing should be performed without delay because normal or low EPO does not rule out PV. [5][6]
• Vitamin B12 levels are frequently elevated in PV and can serve as a supportive laboratory clue. 5

3. Systematic Exclusion of Secondary Erythrocytosis (Even With Normal EPO)

4. Genetic Causes to Consider When PV Is Excluded

• Congenital polycythemia due to EPOR mutations may present with low‑normal EPO levels; this should be evaluated after PV has been ruled out. 5

All bullet points are supported by the cited references.